Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Gains from Sales and Divestitures (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Gains from Sales and Divestitures for 1 consecutive years, with $11568.0 as the latest value for Q4 2016.

  • On a quarterly basis, Gains from Sales and Divestitures changed N/A to $11568.0 in Q4 2016 year-over-year; TTM through Dec 2016 was $11568.0, a N/A change, with the full-year FY2016 number at $11568.0, changed N/A from a year prior.
  • Gains from Sales and Divestitures was $11568.0 for Q4 2016 at Plus Therapeutics.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $11568.0 in Q4 2016 to a low of $11568.0 in Q4 2016.